Funding for this research was provided by:
GlaxoSmithKline (Chair in Neuroscience)
Canadian Institutes of Health Research (MOP 106662)
Received: 7 October 2019
Accepted: 6 July 2020
First Online: 25 July 2020
Ethics approval and consent to participate
: All participants provided informed consent prior to participation in the study. This study was approved by the Queen’s University Health Sciences and Affiliated Teaching Hospitals Research Ethics Board (#ANAT042–05).
: All participants provided consent for publication of their data prior to participation in the study.
: SHS is co-founder and chief scientific officer of Kinarm which commercializes the End-Point robot. Authors CRL, BB, JLM, HB and SPD have no competing interests.